Baran Gundogus

Baran Gundogus

Auto-generated profile, based on publicly available information

Baran Gundogus

Department of Pulmonology, University of Health Sciences, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2023 in Thoracic Research and Practice
Verified
Journal Article
Open access
NKNeslihan Köse Kabil
Neslihan Köse Kabil
ZKZuhal Karakurt
Zuhal Karakurt
BGBaran Gundogus
Baran Gundogus
AGAylin Gungor
Aylin Gungor
KAKubra Akyuz
Kubra Akyuz
HTHatice Turker
Hatice Turker
Respiratory infections,COPD,interstitial lung disease,tuberculosis,respiratory intensive care

22 September 2025 in Tuberk Toraks
Verified
Journal Article
Closed access
BGBaran Gündoğuş
Baran Gündoğuş
TYTekin Yıldız
Tekin Yıldız
MAMeltem Ağca
Meltem Ağca
SÖSelahattin Öztaş
Selahattin Öztaş
ÜAÜlkü Aka Aktürk
Ülkü Aka Aktürk
BOBirsen Ocaklı
Birsen Ocaklı
Sarcoidosis is a chronic and inflammatory multisystemic disease of unknown origin that causes various clinical manifestations. Epidemiologic data vary by numerous variables such as age, geographical location, sex, race, as well as genetic and environmental factors. Epidemiologic data help better characterize the heterogeneous disease of sarcoidosis, as in many other diseases, and facilitate a prognostic assessment. Thus, the present study sought to analyze epidemiologic data and changes in diagnostic strategies used in sarcoidosis over time. The study reviewed patients who were diagnosed with sarcoidosis between January 01, 2011 and December 31, 2020, and had non-necrotizing granulomatous inflammation in at least one thoracic biopsy material. Data from a total of 1.200 patients, of whom 768 (64%) were females and 432 were males (female/male: 1.77), were reviewed over a 10-year period. The results showed an increasing trend in the frequency of sarcoidosis in the 10-year period and an increasing incidence for males after 2015. The rate of asymptomatic patients was 15%, and asymptomatic sarcoidosis was significantly higher in males than in females. After 2012, video-assisted mediastinoscopy was replaced with endobronchial ultrasoundguided transbronchial needle aspiration as the preferred diagnostic technique. Epidemiologic data associated with sarcoidosis are likely to continue changing because of multiple factors such as health policies and technological changes and development. We believe that it is necessary to constantly monitor epidemiological changes in different geographical regions in the world.

23 May 2026 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
RYRabia Yurt
Rabia Yurt
MAMeltem Agca
Meltem Agca
ATAyla Turkar
Ayla Turkar
ETEylem Tunçay
Eylem Tunçay
SGSinem Gungor
Sinem Gungor
IOIpek Ozmen
Ipek Ozmen
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder in which chronic bronchitis and emphysema coexist to varying degrees. Emphysema has distinct clinical and prognostic features. C-reactive protein (CRP), procalcitonin (PCT), white blood cell count (WBC), and neutrophil values are used for diagnosing community-acquired pneumonia (CAP). This study investigated whether these biomarkers differ in emphysematous patients with CAP. Methods: Patients with COPD hospitalized with CAP between January 2016 and February 2023 were divided into emphysema and non-emphysema groups based on radiologic findings. Emphysema subtypes were classified, and quantitative Goddard scoring was performed. Admission demographic, clinical and laboratory data, hospital stay length and clinical outcomes (discharge, intensive care unit [ICU] transfer, in-hospital mortality) were compared between groups. CRP and PCT levels were dichotomized as low and high using predefined thresholds (CRP ≤ 200 vs. >200 mg/L; PCT < 0.10 vs. ≥0.10 µg/L). The independent effect of emphysema on low CRP and PCT levels was assessed using multivariable binary logistic regression analysis. Results: Of the 135 patients included, 71 (53%) had emphysema. Median CRP and PCT levels were significantly lower in the emphysema group than in the non-emphysema group (CRP: 116, interquartile range [IQR] 56–187 vs. 254 (IQR 213-310 mg/L); p < 0.001; PCT: 0.132 [ IQR 0.079–0.536] vs. 0.356 [IQR 0.171–1.660] µg/L; p = 0.007, respectively). Median WBC and neutrophil counts were also lower ( p = 0.036; p = 0.035, respectively). In multivariable analysis, emphysema (odds ratio [OR] 54.274; 95% Confidence Interval [CI] 14.545–202.526; p < 0.001), higher glomerular filtration rate (OR 1.021; 95% CI 1.002–1.040; p = 0.026), and prior antibiotic use (OR 4.278; 95% CI 1.199–15.264; p = 0.025) were independently associated with low CRP. For low PCT, emphysema remained the only significant predictor (OR 3.694; 95% CI 1.145–11.921; p = 0.029). Length of stay was longer in emphysema (9 vs.7 days; p = 0.010), with no differences in ICU transfer or mortality. Conclusion: In patients with emphysema, inflammatory biomarkers at CAP diagnosis were lower compared with those without emphysema. These findings suggest a potential difference in biomarker response; however, the retrospective design limits causality. Further prospective studies are needed to confirm these results and clarify their clinical relevance. Trial registration: Not applicable. This study is a retrospective observational analysis and was not registered as a clinical trial.